瑞莎珠单抗与司库奇尤单抗对比：意大利银屑病患者的真实世界疗效及每位缓解者的成本比较
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy.
作者信息
Pirro Federico, Caldarola Giacomo, Bernardini Nicoletta, Celeste Maria Grazia, Dattola Annunziata, De Luca Eleonora, Galluzzo Marco, Giordano Domenico, Izzi Chiara, Maretti Giulia, Marcelli Lorenzo, Ravasio Roberto, Richetta Antonio Giovanni, Skroza Nevena, Talamonti Marina, Zangrilli Arianna, Bianchi Luca, Pellacani Giovanni, Persechino Severino, Potenza Concetta, Peris Ketty, De Simone Clara
机构信息
UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
出版信息
Dermatol Pract Concept. 2025 Jan 30;15(1):4838. doi: 10.5826/dpc.1501a4838.
INTRODUCTION
Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis.
OBJECTIVES
We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two drugs in a real-life setting.
METHODS
A multicentric retrospective study was conducted in patients from the Lazio region of Italy affected by moderate-to-severe psoriasis who initiated risankizumab or secukinumab between September 2020 to September 2022. Psoriasis Area and Severity Index (PASI) was measured at baseline and after 16, 52, and 78 weeks. Clinical responses were evaluated by PASI90 and PASI100 responses at the same timepoints. The cost per responder at week 16 and 52 was adopted as a cost-effectiveness indicator.
RESULTS
Included were 141 patients, 74 (52.5%) treated with risankizumab and 67 (47.5%) treated with secukinumab. PASI90 responses in risankizumab-treated patients were higher than those observed in patients treated with secukinumab at both weeks 16 and 52 (79.7% versus 64.2% (P = 0.041) and 98.6% versus 83.6% (P = 0.003), respectively). Risankizumab also showed superior PASI100 rates at week 52 (85.5% versus 65.6%, P = 0.009). No statistically significant differences were observed in PASI90 and PASI100 rates between the 2 groups at week 78. The cost per PASI90 and PASI100 responder for risankizumab was lower at both weeks 16 (€5833.66 and €8394.78, compared to €8747.18 and €10746.53 for secukinumab) and 52 (€11798.90 and €13598.73 vs €15347.70 and €19568.31, respectively).
CONCLUSIONS
Risankizumab showed superior efficacy than secukinumab and a lower cost per responder.
引言
司库奇尤单抗和瑞莎珠单抗是治疗中度至重度银屑病患者的有效选择。
目的
我们试图通过在实际临床环境中比较这两种药物，来评估瑞莎珠单抗和司库奇尤单抗的疗效及每位缓解者的成本。
方法
对2020年9月至2022年9月期间在意大利拉齐奥地区开始使用瑞莎珠单抗或司库奇尤单抗治疗的中度至重度银屑病患者进行了一项多中心回顾性研究。在基线以及第16、52和78周时测量银屑病面积和严重程度指数（PASI）。在相同时间点通过PASI90和PASI100反应评估临床反应。采用第16周和第52周时每位缓解者的成本作为成本效益指标。
结果
纳入141例患者，其中74例（52.5%）接受瑞莎珠单抗治疗，67例（47.5%）接受司库奇尤单抗治疗。在第16周和第52周时，接受瑞莎珠单抗治疗的患者的PASI90反应均高于接受司库奇尤单抗治疗的患者（分别为79.7%对64.2%（P = 0.041）和98.6%对83.6%（P = 0.003））。在第52周时，瑞莎珠单抗的PASI100率也更高（85.5%对65.6%，P = 0.009）。在第78周时，两组之间的PASI90和PASI100率未观察到统计学上的显著差异。在第16周和第52周时，瑞莎珠单抗的每位PASI90和PASI100缓解者的成本均较低（第16周时分别为5833.66欧元和8394.78欧元，而司库奇尤单抗为8747.18欧元和10746.53欧元；第52周时分别为11798.90欧元和13598.73欧元，而司库奇尤单抗为15347.70欧元和19568.31欧元）。
结论
瑞莎珠单抗显示出比司库奇尤单抗更高的疗效和更低的每位缓解者成本。
Zotero 插件